Key points from article :
Elastrin Therapeutics Inc. announced the closing of a $10 million funding round led by Kizoo Technology Capital.
Elastrin is a privately held biotechnology company developing therapeutics that render calcified tissue and organs supple again.
Other investors in the round include Starbloom Capital and SC Launch.
The company’s lead asset ELT-001 is an EDTA-loaded nanoparticle conjugated with a proprietary monoclonal antibody for the treatment of vascular calcification.
"Their technology is truly groundbreaking by not only delaying age-related disease but also reversing them.” - Frank Schueler, Managing Director of Kizoo Technology Capital.
Kizoo provides seed and follow-on financing with a focus on rejuvenation biotech.
Elastrin's underlying technology was developed by Dr. Naren Vyavahare over the last 20 years at Clemson University.
SC Launch, Inc. is an independent, non-profit corporation affiliated with SCRA (South Carolina Research Authority).
Starbloom Capital is a crypto-based family office that supports companies developing revolutionary longevity technologies.
